EU nod for Nucala in COPD puts the focus on Monday trade
London, Feb 8, 2026, 08:20 GMT — The market is closed.
- GSK finished Friday at 2,198 pence, up 0.8%, just shy of its recent high.
- The EU has signed off on broader use of GSK’s Nucala for chronic obstructive pulmonary disease.
- Investors are watching for the upcoming dividend dates, and they’re also paying attention to news of an insider buying shares.
GSK (GSK.L) closed Friday at 2,198 pence, up 18 pence, or 0.8%. That puts the drugmaker’s valuation near 88 billion pounds. Shares have climbed roughly 17% this week, and they’ve surged almost 49% over the last year. 1
The market’s closed for the weekend, so investors are left to mull whether GSK’s respiratory drug—now carrying a fresh EU…
